Splashtop Recognized in The Endpoint Management Platforms Landscape Report

CUPERTINO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — Splashtop today announced its inclusion in the Forrester report, The Endpoint Management Platforms Landscape, Q3 20251. Splashtop sees this recognition as acknowledgment of its rising presence in the rapidly evolving endpoint management market. Splashtop's inclusion in the Forrester report comes just months after launching its Autonomous Endpoint […]

No Credit Check Installment Loans Guaranteed Approval: RadCred Introduces AI-Powered Direct Lender Matching for Bad Credit Borrowers

No Credit Check Installment Loans Guaranteed Approval: RadCred Introduces AI-Powered Direct Lender Matching for Bad Credit Borrowers RadCred launches AI-powered direct lender matching for no credit check installment loans with guaranteed approval. Transparent terms for bad credit borrowers. GlobeNewswire September 03, 2025 Glendale, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) — RadCred, a leading U.S.-based AI

Looking to Learn More About The Quran? New Comprehensive Guide Introduces Faith, Life Codes, Science Insights, and More

Looking to Learn More About The Quran? New Comprehensive Guide Introduces Faith, Life Codes, Science Insights, and More Palmetto Publishing Announces The Release of DESCRIPTIVE INDEX OF QURANIC SUBJECTS GlobeNewswire September 03, 2025 Charleston, SC, Sept. 03, 2025 (GLOBE NEWSWIRE) — As author Wasi Zaidi moved through life, he realized a sobering fact: many of

Splashtop Recognized in The Endpoint Management Platforms Landscape Report

Splashtop Recognized in The Endpoint Management Platforms Landscape Report Splashtop attributes the recognition to its growing momentum in autonomous endpoint management, delivering real-time, AI-assisted automation and secure, scalable solutions for modern IT teams. GlobeNewswire September 03, 2025 CUPERTINO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — Splashtop today announced its inclusion in the Forrester report, The

PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight

PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight The outlook for the PDE4B inhibitors market is changing as this drug class demonstrates significant therapeutic promise in respiratory, dermatologic, and inflammatory diseases. Existing approvals such as OHTUVAYRE, ZORYVE, and EUCRISA have already validated the PDE4 mechanism, while pipeline candidates like tanimilast (CHF6001) and

CO-OPERATORS GROWS IN QUEBEC WITH AGENCE D’ASSURANCES MONTCALM ACQUISITION

Co-operators announces its acquisition ofAgence D'Assurances Montcalm Inc. [Montcalm], a brokerage located in Québec City, Québec. The deal closed September 1st, as part of the organization's ongoing strategy to expand their regional footprint. Co-operators, a leading Canadian financial services company, is the fourth largest property and casualty insurer in Canada with over 600 locations coast-to-coast.

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves’ Disease Patients

(NASDAQ:IMVT), First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up period Of the 17 responders to therapy, ~50% (8/17)

Ninebird Properties Expands, Simplifying Home Sales with As-Is Purchases

Plano, Sept. 03, 2025 (GLOBE NEWSWIRE) — Plano, Texas – August 28, 2025 – Ninebird Properties is announcing its expansion across the Dallas-Fort Worth region, making it simpler and faster for homeowners to sell their properties, regardless of the condition or situation. This growth marks a big step for the company, aiming to ease the

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves’ Disease Patients

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients GlobeNewswire September 03, 2025 First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less

Scroll to Top